FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

SinParty Integrates Vibe-Connect Creator Engagement Tools

Creator platform SinParty has partnered with Honey Play Box to add the pleasure brand's Vibe-Connect creator engagement tools.

Hankey's Toys Debuts DiYardieULuv2H8 Silicone Lifecast Dildo

Mr. Hankey's Toys has introduced its newest silicone lifecast dildo, modeled on the anatomy of creator DiYardieULuv2H8.

Blush Expands 'Avant' Line

Blush has introduced two new dildos from its Avant Collection.

Male Power Expands 'Sassy Lace' Collection

Male Power has expanded its new Sassy Lace collection of men's underwear.

Adam & Eve, We-Vibe to Launch Pop-Up Tour

Adam & Eve and We-Vibe have partnered for the nine-city “Experience an Ourgasm” pop-up tour, kicking off July 18.

Salorein Debuts 'Sabrina' Suction Torso

Pleasure brand Salorein has released its new "Sabrina" suction torso.

Toendi Debuts 'Pandora' Stimulator

Toendi has unveiled its new Pandora clitoral stimulator.

Beisar Introduces 'Phantom' Dildo

Beisar has debuted its Phantom fantasy dildo.

Full Circle to Debut New Pleasure Products at ANME

Full Circle will introduce its new AI companion love dolls and head-equipped torso dolls at ANME trade show, running July 12-15 at the Burbank Marriott.

Our Erotic Journey Rolls Out Store Locator Site Feature

Our Erotic Journey (OEJ) has debuted its new Store Locator feature on its website and app.

Show More